Investment Rating - The industry maintains a "Recommended" rating, focusing on service consumption, beauty care, IP derivatives, and gold jewelry as new consumption sectors [5][26]. Core Insights - The total retail sales of social consumer goods in January-February 2026 reached 8.61 trillion yuan, a year-on-year increase of 2.8%, exceeding the Wind consensus expectation of 2.5% [3][23]. - Retail sales of goods amounted to 7.58 trillion yuan, up 2.5% year-on-year, while service retail sales grew by 5.6%, and catering revenue reached 1.03 trillion yuan, increasing by 4.8% [3][23]. - The long Spring Festival holiday boosted travel willingness, leading to faster growth in service consumption, with retail sales in tourism consulting and leisure services maintaining over 10% growth [3][23]. Summary by Sections Market Performance - From March 16 to March 20, 2026, the commerce retail, social services, and beauty care sectors experienced declines of 4.55%, 4.00%, and 4.78% respectively, ranking 18th, 14th, and 21st among 31 primary industries [13][21]. Key Industry Data and News - In the beauty care sector, Up Beauty Co. signed a strategic cooperation framework agreement with KAITAI Pharmaceutical regarding KT-939, aiming to enhance its market position in effective whitening cosmetics [23]. - The 2025 financial results for major companies showed mixed performance, with Juzhi Bio reporting a slight revenue decline of 0.4% to 5.518 billion yuan and a net profit drop of 7.2% [23][25]. - Watsons Group's 2025 revenue in China was 13.265 billion HKD, down 1.8%, with EBITDA falling sharply by 73.88% [23][25]. Investment Recommendations - The report emphasizes a focus on service consumption, beauty care, IP derivatives, and gold jewelry sectors, recommending specific companies such as Ruoyuchen, Maogeping, Up Beauty Co., Pop Mart, Chaohongji, and Laopu Gold [5][26].

Investment Rating - The report maintains an "Overweight" rating for the industry, focusing on service consumption, beauty care, IP derivatives, and gold jewelry as key sectors for investment opportunities [5][26]. Core Insights - The total retail sales of social consumer goods in January-February 2026 reached 8.61 trillion yuan, a year-on-year increase of 2.8%, exceeding the consensus expectation of 2.5% [3][23]. - The retail sales of goods amounted to 7.58 trillion yuan, with a year-on-year growth of 2.5%, while service retail sales grew by 5.6% [3][23]. - The report highlights the impact of the extended Spring Festival holiday on consumer spending, particularly in service consumption, with categories like tourism and leisure services showing over 10% growth [3][23]. Summary by Sections Market Performance - For the week of March 16-20, 2026, the performance of the commerce retail, social services, and beauty care sectors was -4.55%, -4.00%, and -4.78% respectively, ranking 18th, 14th, and 21st among 31 primary industries [13][21]. Key Industry Data and News - In the beauty care sector, companies like Shangmei and Juzhi Bio reported mixed results, with Shangmei entering a strategic partnership for a new cosmetic ingredient, while Juzhi's revenue slightly declined [3][23][25]. - The travel sector saw a total of approximately 106,000 passenger flights executed nationwide in the 12th week of 2026, reflecting a year-on-year increase of 4% [4][23]. - In the IP derivatives space, Pop Mart announced a collaboration with Sony Pictures to develop a live-action animated film, indicating growth potential in this segment [4][23]. Investment Recommendations - The report suggests focusing on companies such as Ruoyuchen, Maogeping, Shangmei, Pop Mart, Chaohongji, and Laopu Gold as potential investment targets within the highlighted sectors [5][26].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 155.04 [7]. Core Insights - The company is expected to achieve revenue of RMB 2.453 billion in 2025, a year-on-year decrease of 18.94%, and a net profit attributable to the parent company of RMB 1.291 billion, down 34.05% year-on-year. This decline is attributed to the medical beauty industry entering a mature and regulated phase, leading to intensified competition and slowing growth [1][5]. - The company has a rich pipeline of products, with new approvals progressing steadily. The recent approval of a botulinum toxin product and the registration of minoxidil lotion are expected to contribute positively to future revenues [4][5]. - The company is actively expanding its product lines, particularly in the freeze-dried powder category, which has shown significant revenue growth. The introduction of new products is anticipated to create new growth points and potentially restore revenue growth in 2026 [2][5]. Summary by Sections Financial Performance - In 2025, the company reported a gross margin of 92.7%, a decrease of 1.95 percentage points year-on-year. The gross margin for solution products was 93.1%, and for gel products, it was 97.3% [3]. - The sales expense ratio increased to 15.8%, primarily due to higher personnel costs and increased expenses related to sales activities [3]. Product Sales Structure - The revenue from solution injection products was RMB 1.265 billion, down 27.48% year-on-year, accounting for 51.57% of total revenue. Gel injection products generated RMB 890 million, down 26.82%, making up 36.27% of total revenue. Freeze-dried powder injection products contributed RMB 208 million, accounting for 8.48% [2]. Pipeline and New Products - The company has made significant progress in its product pipeline, with several products entering the registration and approval stages. The approval of the botulinum toxin product is particularly noteworthy as it is the seventh compliant product of its kind approved in China [4]. Earnings Forecast and Valuation - The revenue forecast for 2026 is adjusted to RMB 2.829 billion, reflecting a growth of 15.33% year-on-year. The net profit forecast for 2026 is slightly reduced to RMB 1.422 billion, down 14.9% from previous estimates [5][11]. - The company is valued at a price-to-earnings ratio of 33 times, with a target price adjustment reflecting a premium rate [5].

Core Viewpoint - Aimeike's stock price has increased by 5.09% on February 5, reaching 155.87 CNY per share, with a total market capitalization of 47.165 billion CNY, marking a cumulative increase of 6.15% over three consecutive days [1] Group 1: Company Overview - Aimeike Technology Development Co., Ltd. is located in Chaoyang District, Beijing, and was established on June 9, 2004, with its IPO on September 28, 2020 [1] - The company's main business involves the research, production, and sales of biomedical soft tissue repair materials, with revenue composition as follows: 57.27% from solution injection products, 37.97% from gel injection products, 3.01% from others, 1.50% from freeze-dried powder injection products, and 0.26% from facial implant threads [1] Group 2: Shareholder Insights - Huatai-PB Fund's Huatai-PB CSI 300 ETF (510300) is among Aimeike's top ten circulating shareholders, having reduced its holdings by 85,400 shares to 2.6773 million shares, representing 1.28% of circulating shares [2] - The ETF has generated a floating profit of approximately 20.2138 million CNY today and 22.9982 million CNY during the three-day increase [2] - The Huatai-PB CSI 300 ETF was established on May 4, 2012, with a current scale of 422.258 billion CNY, yielding 1.56% this year and 26.25% over the past year [2] Group 3: Fund Performance - The Huatai-PB Health ETF (516790) has also heavily invested in Aimeike, having reduced its holdings by 5,700 shares to 18,900 shares, accounting for 2.73% of the fund's net value [3] - The ETF has achieved a floating profit of approximately 142,500 CNY today and 162,200 CNY during the three-day increase [3] - The Huatai-PB Health ETF was established on August 12, 2021, with a current scale of 98.1452 million CNY, yielding 6.43% this year and 12.82% over the past year [3]

Core Viewpoint - Aimeike's stock price has shown a slight decline this year, with a recent increase of 2.01% on January 29, 2025, but overall performance indicates a downward trend in the past months, raising concerns about its financial health and market position [1][2]. Financial Performance - For the period from January to September 2025, Aimeike reported a revenue of 1.865 billion yuan, representing a year-on-year decrease of 21.49%. The net profit attributable to shareholders was 1.093 billion yuan, down 31.05% compared to the previous year [2]. - Cumulative cash dividends since Aimeike's A-share listing amount to 3.887 billion yuan, with 3.012 billion yuan distributed over the last three years [3]. Shareholder and Market Activity - As of January 20, 2025, Aimeike had 61,700 shareholders, an increase of 0.42% from the previous period. The average number of circulating shares per shareholder decreased by 0.42% to 3,379 shares [2]. - On January 29, 2025, Aimeike's stock price was 140.89 yuan per share, with a total market capitalization of 42.632 billion yuan. The trading volume was 314 million yuan, with a turnover rate of 1.08% [1]. Business Overview - Aimeike, established on June 9, 2004, and listed on September 28, 2020, specializes in the research, production, and sales of biomedical soft tissue repair materials. Its main revenue sources include solution injection products (57.27%), gel injection products (37.97%), and others [1]. - The company operates within the beauty care and medical aesthetics industry, focusing on medical beauty consumables, and is associated with concepts such as weight loss drugs and cosmetics [1]. Institutional Holdings - As of September 30, 2025, Aimeike's top ten circulating shareholders included Hong Kong Central Clearing Limited, holding 6.8295 million shares (a decrease of 151,300 shares), and Huabao Zhongzheng Medical ETF, holding 4.2589 million shares (a decrease of 802,100 shares) [3].

Core Viewpoint - The stock price of Aimeike has shown fluctuations, with a recent decline of 2.02% and a total market capitalization of 44.998 billion yuan as of January 15. The company has experienced a net outflow of funds, indicating potential investor concerns [1]. Group 1: Stock Performance - Aimeike's stock has increased by 4.93% year-to-date, with a 1.86% rise over the last five trading days and a 5.80% increase over the last 20 days. However, it has seen a decline of 11.38% over the past 60 days [2]. - As of January 9, the number of Aimeike's shareholders has increased to 61,500, up by 2.32%, while the average circulating shares per person decreased by 2.27% to 3,393 shares [2]. Group 2: Financial Performance - For the period from January to September 2025, Aimeike reported a revenue of 1.865 billion yuan, representing a year-on-year decrease of 21.49%. The net profit attributable to the parent company was 1.093 billion yuan, down 31.05% year-on-year [2]. - Aimeike has distributed a total of 3.887 billion yuan in dividends since its A-share listing, with 3.012 billion yuan distributed over the last three years [3]. Group 3: Shareholder Composition - As of September 30, 2025, the sixth-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 6.8295 million shares, a decrease of 151,300 shares from the previous period. Other notable shareholders include Hua Bao Zhong Zheng Medical ETF and Yi Fang Da Growth Enterprise Board ETF, both of which have also seen reductions in their holdings [3].

Core Viewpoint - The stock of Aimeike has shown a mixed performance with a recent increase in price, but the company has reported a significant decline in revenue and net profit for the year 2025. Group 1: Stock Performance - On January 8, Aimeike's stock rose by 2.00%, reaching 148.25 yuan per share, with a trading volume of 315 million yuan and a turnover rate of 1.03%, resulting in a total market capitalization of 44.859 billion yuan [1] - Year-to-date, Aimeike's stock price has increased by 4.61%, with a 4.96% rise over the last five trading days, a 5.01% increase over the last 20 days, but a decline of 15.52% over the last 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Aimeike reported an operating revenue of 1.865 billion yuan, a year-on-year decrease of 21.49%, and a net profit attributable to shareholders of 1.093 billion yuan, down 31.05% year-on-year [2] - Since its A-share listing, Aimeike has distributed a total of 3.887 billion yuan in dividends, with 3.012 billion yuan distributed over the past three years [3] Group 3: Shareholder Information - As of December 31, Aimeike had 60,100 shareholders, a decrease of 2.71% from the previous period, with an average of 3,472 circulating shares per person, an increase of 2.78% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, holding 6.8295 million shares (a decrease of 151,300 shares), and Huabao CSI Medical ETF, holding 4.2589 million shares (a decrease of 802,100 shares) [3]

Core Viewpoint - Aimeike's stock price has shown a slight increase of 2.03% this year, with fluctuations in trading performance over various time frames, indicating a mixed market sentiment towards the company [2]. Group 1: Stock Performance - As of January 5, Aimeike's stock price reached 144.60 yuan per share, with a trading volume of 3.75 billion yuan and a market capitalization of 437.55 billion yuan [1]. - Year-to-date, Aimeike's stock has increased by 2.03%, with a 0.77% rise over the last five trading days and a 2.98% increase over the last 20 days, while experiencing a decline of 19.85% over the past 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Aimeike reported a revenue of 1.865 billion yuan, representing a year-on-year decrease of 21.49%, and a net profit attributable to shareholders of 1.093 billion yuan, down 31.05% year-on-year [2]. Group 3: Business Overview - Aimeike, established on June 9, 2004, and listed on September 28, 2020, specializes in the research, production, and sales of biomedical soft tissue repair materials [2]. - The company's revenue composition includes 57.27% from solution-based injection products, 37.97% from gel-based injection products, 3.01% from other products, 1.50% from freeze-dried powder injection products, and 0.26% from facial implant lines [2]. Group 4: Shareholder Information - As of December 19, Aimeike had 61,700 shareholders, an increase of 2.23% from the previous period, with an average of 3,378 circulating shares per shareholder, a decrease of 2.18% [2]. - The company has distributed a total of 3.887 billion yuan in dividends since its A-share listing, with 3.012 billion yuan distributed over the last three years [3].

Core Insights - Aimeike's stock price increased by 2.04% to 159.69 CNY per share as of November 11, with a total market capitalization of 48.32 billion CNY [1] - The company has experienced a year-to-date stock price decline of 10.04%, but a recent 5-day increase of 5.11% [1][2] - Aimeike's main business involves the research, production, and sales of biomedical soft tissue repair materials, with a revenue composition primarily from injection products [1] Financial Performance - For the period from January to September 2025, Aimeike reported a revenue of 1.865 billion CNY, a year-on-year decrease of 21.49%, and a net profit of 1.093 billion CNY, down 31.05% year-on-year [2] - Cumulative cash dividends since Aimeike's A-share listing amount to 3.887 billion CNY, with 3.012 billion CNY distributed over the past three years [3] Shareholder Information - As of October 31, 2025, Aimeike had 57,400 shareholders, an increase of 2.63% from the previous period, with an average of 3,630 circulating shares per shareholder, a decrease of 2.56% [2] - Major shareholders include Hong Kong Central Clearing Limited and various ETFs, with notable reductions in their holdings [3]

Core Insights - Aimeike is a leading player in the domestic medical aesthetics industry, focusing on the research and development of biological medical soft tissue repair materials, with strong technical barriers and product matrix advantages [1] Financial Performance - In Q3 2025, Aimeike reported revenue of 1.865 billion yuan, ranking second in the industry, while the industry leader, Huaxi Biological, achieved revenue of 3.163 billion yuan [2] - The company's net profit for the same period was 1.107 billion yuan, ranking first in the industry, with the second-ranked Jinbo Biological reporting a net profit of 565 million yuan [2] Financial Ratios - Aimeike's debt-to-asset ratio stood at 8.20% in Q3 2025, significantly lower than the industry average of 16.58%, indicating strong solvency [3] - The gross profit margin for the same period was 93.36%, higher than the industry average of 84.95%, reflecting robust profitability [3] Executive Compensation - Chairman Jian Jun's salary decreased from 2.5144 million yuan in 2023 to 2.49 million yuan in 2024, a reduction of 24,400 yuan [4] - General Manager Shi Yifeng's salary also saw a decrease from 2.955 million yuan in 2023 to 2.69 million yuan in 2024, a reduction of 265,000 yuan [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.10% to 56,300, while the average number of circulating A-shares held per shareholder increased by 0.10% to 3,704.54 [5] - Major shareholders, including Hong Kong Central Clearing Limited and various ETFs, have reduced their holdings [5] Business Highlights - Aimeike completed the acquisition of a controlling stake in South Korea's Regen Company, expanding its international market presence [5] - The company's subsidiary, Beijing Nobomin, received certification for Minoxidil topical solution, marking a significant milestone in product development [5] - Ongoing clinical trials for products like the second-generation implant line and the Sumei injection are expected to progress towards registration by the end of 2025 [5]